230MO First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies von Krebs, M.G., Lord, S., Kenny, L., Baird, R.D., MacPherson, I., Bahl, A., Clack, G., Ainscow, E., Barrett, A.G., Dickinson, P., Fuchter, M.J., Lehnert, M., Ali, S., Mcintosh, S., Coombes, R.C.

Volltext